Prevalence of Factor V Leiden Is Not Increased in Women with Recurrent Miscarriage

Abstract

The purpose of this study was to determine if there is an increased prevalence of the thrombophilic genetic mutant factor V Leiden in patients with recurrent miscarriage. Functional assays were conducted for activated protein C resistance and genetic detection of factor V Leiden in 100 women with recurrent miscarriage compared with a control group. The prevalence of factor V Leiden in patients was 6/100 (6%) compared with 3/85 (3.5%) in controls. The difference was not statistically significant. Antithrombotic prophylaxis with heparin and/ or aspirin in a subsequent pregnancy in five of the six patients with factor V Leiden was associated with maintenance of pregnancy and delivery of a live, healthy, full-term infant in four. We have been unable to demonstrate a statistically significant increased prevalence of factor V Leiden in women with recurrent miscarriage. If antithrombotic prophylaxis in pregnancy can be shown by controlled therapeutic trial to prevent miscarriage in these patients, identification of this subgroup would be important. Key Words: Recurrent miscarriage—Factor V Leiden—Activated protein C resistance.

Get full access to this article

View all access options for this article.

References

Dahlback B. , Carlsson M. , Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl A cad Sci USA 1993;90:1004-8.

Koster T. , Rosendaal FR , de Ronde H. , Briet E. , Vanden-' broucke JP , Bertina M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993 ;342:1503-6.

Griffin JH , Evatt B. , Wideman C. , Fernandez JA Anticoagulant protein C pathway defective in majority of thrombophilic patients . Blood 1993;82:1989-93.

Dahlback B. , Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-400.

Bertina RM , Koeleman Bpc , Koster T. , et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.

Voorberg J. , Roelse J. , Koopman R. , et al. Association of idiopathic venous thromboembolism with single point-mutation at Args506 of factor V. Lancet 1994;343:1535-6.

Zoller B. , Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994 ;343: 1536-8.

Svensson PJ , Dahlback B. Resistance to activated protein C as a basis for venous thrombosis . N Engl J Med 1994;330: 517-22.

Greengard JS. Sun X. , Xu X. , Fernandez JA , Griffin JH , Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361-2.

10.

Halbmayer WM , Haushofer A. , Schon R. , Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects . Blood Coagitl Fibrinolysis 1994;5:51-7.

11.

Legnani C. , Palareti G. , Biagi R. , Coccheri S. Activated protein C resistance in deep-vein thrombosis. Lancet 1994;343: 541-2.

12.

Beauchamp NJ , Daly ME , Hampton KK , Cooper PC , Preston FE , Peake IR High prevalence of a mutation in the factor V gene within the UK population; relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994 ;88:219-22.

13.

Rai R. , Regan L. , Hadley E. , Dave M. , Cohen H. Second trimester pregnancy loss is associated with activated protein C iresistance [Abstract]. Proc. XVth congress of the international society on thrombosis and haemostasis, Jerusalem, 1995.

14.

Saiki RK Gelfand DH , Stoffel S. , et al. Primer-directed enzyme amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487.

15.

Stirling D. , White A. , Clarkson J. , Stewart A. , Ludlam CA Both functional and genetic testing are required for diagnosis of activated protein-C resistance (APCR) [Abstract]. Br J Haematal 1995;89(suppl 1):7.

16.

Cumming AM , Tait RC , Fildes S. , Yoong A. , Keeney S. , Hay Crm. Activated protein C resistance in pregnancy [Abstract]. Proc. XVth congress of the international society on thrombosis and haemostasis , Jerusalem, 1995.

17.

Faioni EM , Franchi F. , Asti D. , Mannucci PM Acquired resistance to activated protein C develops during pregnancy [Abstract] . Proc. XVth congress of the international society on thrombosis and haemostasis, Jerusalem, 1995.

18.

Bokarewa MI , Blomback M. , Bremme K. Changes in the response to activated protein C during pregnancy [Abstract]. Proc. XVth congress of the international society on thrombosis and haemostasis, Jerusalem, 1995.

19.

De Stefano V. , Mastrangeto S. , Paciaroni K. , et al. Prevalence of venous thrombosis in pregnant women with APC-resistance: a retrospective study [Abstract]. Proc. XVth congress of the international society on thrombosis and haemo— stasis, Jerusalem , 1995.